In this tHEORetically Speaking episode, Paige McGarry from HealthEconomics.com speaks with David W. Miller, Chief Executive Officer at Genesis Research Group, exploring the distinctive obstacles biotech firms encounter in developing evidence, securing market access, and engaging key stakeholders.
Small to mid-sized biotech companies frequently encounter well-known resource limitations that create significant barriers. Many of these organizations struggle with insufficient internal capabilities and the specialized knowledge needed to effectively bridge the gap between preclinical/clinical phases and achieving commercial viability. Despite these constraints, the urgency to establish value and demonstrate meaningful advancement persists, especially given the increasing volatility within the biotechnology sector.
This reality highlights how conventional consulting approaches fall short and prove insufficient for addressing client requirements in today’s dynamic and intricate global marketplace environment.
During this conversation, David W. Miller explores Genesis Research Group’s approach to tackling these obstacles, covering topics such as the critical nature of early-stage value demonstration, how real-world evidence supports biotech organizations, biotech resourcing, and methods for managing uncertainty across the biotechnology industry. The discussion also covers strategic approaches to data gathering while highlighting the essential role of agility and responsiveness within the dynamic life sciences field.
The interview features Genesis Research Group’s Flexible Integrated Team (FIT) methodology, presented as a customizable and purpose-built framework designed to assist biotech companies in optimizing both development and market launch phases, accommodating varying organizational sizes, resource levels, and unique requirements. Miller describes this as a fundamental transformation in strategic collaboration, detailing how Genesis leverages their comprehensive international experience across pricing strategies, real-world evidence, health economics and outcomes research (HEOR), and market access to guide emerging biotechnology companies toward commercial achievement.
